Nizar J Bahlis

Targets

• BCMA 1
• GPRC5D 1

Filled chips are declared by the researcher; the others come from publications (number of works).

Now

Trials, publications and grants since Nov 2024.

• Publication

  Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

  Nature medicine, Jan 2026

• Preprint

  Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

  bioRxiv : the preprint server for biology, Dec 2025

• Publication

  Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Dec 2025

• Publication

  Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

  The New England journal of medicine, Dec 2025

Affiliations

• University of Calgary

Co-authors

• SIShinsuke IidaHow are we linked?

Who links you

Enter another researcher's profile link or ID to see who has published with both of you.